For years, you’ve been replacing your patient’s testosterone. Maybe it’s time to consider replacing how it’s delivered. While there have been frequent, and prominent, new products developed for treating hypogonadism in the last 20 years, one particular type of option has been scarce – and it may be the one that patients want and/or prefer. […]
Lipocine Inc. announced that the specialty pharmaceutical company received a Complete Response Letter (“CRL”) from the FDA regarding its New Drug Application for TLANDO, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.
Allergan is buying Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018.
Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene THE WOODLANDS, Texas, Dec. 1, 2015 (GLOBE NEWSWIRE) — Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application for enclomiphene for the treatment of secondary hypogonadism in […]